Lv5
1180 积分 2025-01-17 加入
A Simple Guide to Effect Size Measures
26天前
已完结
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial
1个月前
已完结
Phase Ib Trial of Fulvestrant, Palbociclib, and Erdafitinib, a pan-FGFR Tyrosine Kinase Inhibitor, in HR+/HER2− Metastatic Breast Cancer
2个月前
已关闭
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions
2个月前
已完结
Single–amino acid variants in target epitopes can confer resistance to antibody-based therapies
2个月前
已完结
Macrophage-targeted immunocytokine leverages myeloid, T, and NK cell synergy for cancer immunotherapy
2个月前
已完结
Sequencing antibody–drug conjugates in metastatic breast cancer: A systematic review
2个月前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
3个月前
已完结
Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC
3个月前
已完结
Multi-Institution Analysis of Tarlatamab for the Treatment of EGFR -Mutant Transformed Small Cell Lung Cancer
3个月前
已关闭
皖公网安备34019202002308
